title: Interleukin-2 and cancer: critical analysis of results, problems and expectations.
abstract: The cancer process in a combination of two kinds of events: a multistep cellular genetic defects giving cells independent growth and great adaptation capability, a multistep interactions profiles with what is called the stromal reaction from the original in situ tumor to the invasive metastatic and angiogenic tumor. The immune system plays an important role in the control of the cancer process but always must be seen as a part integrated in the stromal reaction. In order to boost the immune system capability to treat a cancer we must never forget these cellular and tissular dimensions. Interleukins, growth factors and monoclonal antibodies are new agents are able to bring immunotherapy of cancer to reality. Interleukin 2 did not match our dreams of the ideal factor which can stimulate the defective immune system and bring the cancer evolution to an end. The little but real remissions obtained with the IL-2 high dose protocols still sustains our trust of the immune system as a critical barrier to cancer evolution but the numerous side effects reminds us that cytokines are not to be used as antibiotics and hormones. IL-2 is a regulator of the immune system at the microenvironment level, therefore flooding the blood circulation with high IL-2 doses is not appropriate. We have also to understand that IL-2 can interact directly with cancer cells and also with stromal cells (endothelial and fibroblastic cells), the outcome of IL-2 immunotherapy is not restricted to the interactions with immune cells.
authors.affiliation: 6 Rue Abdesslem Ennabli 4000, Sousse, Tunisia. a_alileche@hotmail.com
authors.forename: Abdelkrim
authors.initials: A
authors.lastname: Alileche
mesh_terms: D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007211:Indoles / Q000494:pharmacology; D007376:Interleukin-2 / Q000378:metabolism*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000378:metabolism*; D009389:Neovascularization, Pathologic; D000078183:Oxindoles; D011422:Propionates; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000378:metabolism
chemical_list: D016207:Cytokines; D007211:Indoles; D007376:Interleukin-2; D000078183:Oxindoles; D011422:Propionates; D011758:Pyrroles; D015375:Receptors, Interleukin-2; C116890:Semaxinib; C412603:orantinib; D011505:Protein-Tyrosine Kinases